Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wild Chrysanthemum Injection (野菊花注射液) is a traditional Chinese medicine (TCM) injection developed by Shanhaidan Pharmaceutical, derived from the extract of the flower heads of *Chrysanthemum indicum* L. It is primarily utilized for its heat-clearing and detoxifying properties, which are central to TCM therapeutic strategies for inflammatory and infectious conditions. The injection is clinically indicated for the treatment of upper respiratory tract infections and acute tonsillitis. Pharmacological studies indicate that the extract possesses broad-spectrum antibacterial, antiviral, and anti-inflammatory activities, effectively inhibiting various respiratory pathogens and modulating inflammatory cytokine production. It is typically administered via intramuscular injection and is an approved pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wild chrysanthemum injection.